Direct Answer
GLP-1 is a native incretin hormone that regulates insulin secretion and appetite; its analogs (not native GLP-1) are the approved GLP-1 receptor agonist drugs.
Summary Table
Evidence Level
High
AI Summary
GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone released from intestinal L-cells that regulates glucose-dependent insulin secretion, gastric emptying, and appetite. The physiology of native GLP-1 is well established (high-quality reviews), but native GLP-1 is not itself a marketed product: it is rapidly degraded by DPP-4 and has a very short half-life. The approved medicines in this class are longer-acting GLP-1 receptor agonist analogs (such as semaglutide and liraglutide), which are covered separately. This entry describes the native hormone, not a supplement or research chemical to take.
Key Information
Classification
Key Takeaways
- GLP-1 is a native incretin hormone regulating insulin secretion, gastric emptying, and appetite
- Its physiology is well established, but the native hormone is rapidly degraded and not a practical therapy
- The approved GLP-1 medicines are longer-acting analogs (e.g. semaglutide), covered separately
Scientific Overview
In Plain English
GLP-1 is a natural gut hormone your body releases after eating. It helps control blood sugar and appetite. The native hormone breaks down within minutes, so it is not sold as a product; the well-known GLP-1 medicines (like semaglutide) are longer-lasting lab-made versions. This page describes the natural hormone itself.
Scientific Details
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. It acts at the GLP-1 receptor to potentiate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, and it has additional described actions in the cardiovascular system. Native GLP-1 is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4), giving a half-life of a few minutes; therapeutic use relies on DPP-4-resistant receptor agonist analogs or DPP-4 inhibitors rather than the native peptide.
How It Works
GLP-1 is described as an incretin hormone acting at the GLP-1 receptor, associated with glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and reduced appetite. These physiological actions are well characterized; the native hormone is rapidly degraded by DPP-4, which is why long-acting analogs are used therapeutically.
Mechanism of Action
GLP-1 receptor signaling (incretin effect)
human
Native GLP-1 activates the GLP-1 receptor, associated with glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and reduced appetite.
Rapid DPP-4 inactivation
human
Native GLP-1 is rapidly cleaved and inactivated by dipeptidyl peptidase-4, giving a very short half-life and motivating the use of resistant analogs.
Evidence Level
Human Evidence
The physiology of native GLP-1 is well established through extensive human and mechanistic research; the therapeutic evidence base concerns its long-acting analogs rather than the native peptide.
Animal Evidence
Preclinical work characterized GLP-1 receptor pharmacology and incretin physiology.
Limitations
Native GLP-1 is not a practical therapeutic due to its very short half-life; clinical benefit is established for analog drugs (covered separately), not for administering the native hormone.
Why This Grade
Graded high for the physiology of the native hormone, which is well established in the literature. Note this grade describes established incretin physiology, not any product or supplement use of native GLP-1, which is impractical due to rapid degradation.
References
- The physiology of glucagon-like peptide 1. Physiological Reviews.Reviewdoi:10.1152/physrev.00034.2006 →
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism.Reviewdoi:10.1016/j.cmet.2018.03.001 →
- The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metabolism.Reviewdoi:10.1016/j.cmet.2016.06.009 →
Alternative Names
- Glucagon-like peptide-1
- GLP-1(7-37)
- Native incretin hormone
Risks & Safety
- Native GLP-1 is not a marketed product; it is not something to obtain or self-administer
- Its extremely short half-life makes native GLP-1 impractical as a therapy
- Therapeutic effects and their associated risks apply to GLP-1 receptor agonist analog drugs (covered separately), not the native hormone
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Consult a licensed healthcare provider. This entry describes the endogenous hormone GLP-1 and is not a recommendation to use any product; therapeutic evidence concerns approved analog medicines covered separately.
This page summarizes published research and is for informational purposes only; it is not medical advice.